Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2015 | OS after adjustment for crossover in a study of idelalisib with rituximab for relapsed CLL

Paolo Ghia • 12 Jun 2015
EHA 2015
Chronic Lymphocytic Leukemia Idelalisib Rituximab

At the 20th Congress of the European Hematology Association (EHA), Paolo Ghia, MD, PhD, of Università Vita-Salute San Raffaele, Milan, Italy, discusses the overall survival (OS) analysis adjusting for treatment effect after crossover in a phase 3 study evaluating the PI3K delta inhibitor, idelalisib, in combination with rituximab in patients with relapsed chronic lymphocytic leukemia (CLL).

More from Paolo Ghia

Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease 19:55
Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease
Arnon Kater et al. • 25 Apr 2025
A study investigating the efficacy of CAR-T therapy in Richter’s transformation 1:52
A study investigating the efficacy of CAR-T therapy in Richter’s transformation
Paolo Ghia • 27 Sep 2024
A study investigating outcomes for a rare subgroup of CLL with CNS involvement 2:17
A study investigating outcomes for a rare subgroup of CLL with CNS involvement
Paolo Ghia • 27 Sep 2024
The future of CLL treatment: aiming for long-lasting remission 1:42
The future of CLL treatment: aiming for long-lasting remission
Paolo Ghia • 27 Sep 2024

Related Videos

Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study 3:24
Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study
Nirav Niranjan Shah • 24 Sep 2025
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines 1:56
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines
Nirav Niranjan Shah • 24 Sep 2025
BTK degraders in CLL: how may these agents shape the field? 1:30
BTK degraders in CLL: how may these agents shape the field?
Nirav Niranjan Shah • 24 Sep 2025
The importance of understanding the mechanisms underlying Richter’s transformation 1:15
The importance of understanding the mechanisms underlying Richter’s transformation
Gianluca Gaidano • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals